vs
Side-by-side financial comparison of Hologic (HOLX) and Life Time Group Holdings, Inc. (LTH). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $745.1M, roughly 1.4× Life Time Group Holdings, Inc.). Hologic runs the higher net margin — 17.1% vs 16.5%, a 0.6% gap on every dollar of revenue. On growth, Life Time Group Holdings, Inc. posted the faster year-over-year revenue change (12.3% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $-64.6M). Over the past eight quarters, Life Time Group Holdings, Inc.'s revenue compounded faster (11.7% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Life Time Group Holdings, Inc. operates a network of premium athletic, fitness and wellness destinations across the United States. It offers diverse services including state-of-the-art gym facilities, group exercise classes, personal training, spa treatments, nutrition coaching, youth programs and co-working spaces for consumers pursuing holistic healthy lifestyles.
HOLX vs LTH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $745.1M |
| Net Profit | $179.1M | $123.0M |
| Gross Margin | 56.0% | 49.1% |
| Operating Margin | 22.6% | 17.4% |
| Net Margin | 17.1% | 16.5% |
| Revenue YoY | 2.5% | 12.3% |
| Net Profit YoY | -10.9% | 231.0% |
| EPS (diluted) | $0.79 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $745.1M | ||
| Q3 25 | $1.0B | $782.6M | ||
| Q2 25 | $1.0B | $761.5M | ||
| Q1 25 | $1.0B | $706.0M | ||
| Q4 24 | $1.0B | $663.3M | ||
| Q3 24 | $988.0M | $693.2M | ||
| Q2 24 | $1.0B | $667.8M | ||
| Q1 24 | $1.0B | $596.7M |
| Q4 25 | $179.1M | $123.0M | ||
| Q3 25 | $187.2M | $102.4M | ||
| Q2 25 | $194.9M | $72.1M | ||
| Q1 25 | $-17.4M | $76.1M | ||
| Q4 24 | $201.0M | $37.2M | ||
| Q3 24 | $178.6M | $41.4M | ||
| Q2 24 | $194.5M | $52.8M | ||
| Q1 24 | $169.9M | $24.9M |
| Q4 25 | 56.0% | 49.1% | ||
| Q3 25 | 55.6% | 47.1% | ||
| Q2 25 | 56.3% | 47.0% | ||
| Q1 25 | 37.5% | 47.5% | ||
| Q4 24 | 56.8% | 48.2% | ||
| Q3 24 | 56.4% | 46.5% | ||
| Q2 24 | 55.4% | 46.8% | ||
| Q1 24 | 53.3% | 46.1% |
| Q4 25 | 22.6% | 17.4% | ||
| Q3 25 | 22.6% | 17.3% | ||
| Q2 25 | 24.9% | 14.2% | ||
| Q1 25 | -0.7% | 15.2% | ||
| Q4 24 | 22.5% | 13.1% | ||
| Q3 24 | 23.3% | 13.5% | ||
| Q2 24 | 24.1% | 15.7% | ||
| Q1 24 | 20.7% | 12.1% |
| Q4 25 | 17.1% | 16.5% | ||
| Q3 25 | 17.8% | 13.1% | ||
| Q2 25 | 19.0% | 9.5% | ||
| Q1 25 | -1.7% | 10.8% | ||
| Q4 24 | 19.7% | 5.6% | ||
| Q3 24 | 18.1% | 6.0% | ||
| Q2 24 | 19.2% | 7.9% | ||
| Q1 24 | 16.7% | 4.2% |
| Q4 25 | $0.79 | $0.55 | ||
| Q3 25 | $0.84 | $0.45 | ||
| Q2 25 | $0.86 | $0.32 | ||
| Q1 25 | $-0.08 | $0.34 | ||
| Q4 24 | $0.87 | $0.17 | ||
| Q3 24 | $0.75 | $0.19 | ||
| Q2 24 | $0.82 | $0.26 | ||
| Q1 24 | $0.72 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $204.8M |
| Total DebtLower is stronger | $2.5B | $1.5B |
| Stockholders' EquityBook value | $5.2B | $3.1B |
| Total Assets | $9.2B | $8.0B |
| Debt / EquityLower = less leverage | 0.48× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $204.8M | ||
| Q3 25 | $2.2B | $218.9M | ||
| Q2 25 | $1.9B | $175.5M | ||
| Q1 25 | $1.6B | $59.0M | ||
| Q4 24 | $2.0B | $10.9M | ||
| Q3 24 | $2.3B | $120.9M | ||
| Q2 24 | $2.4B | $34.5M | ||
| Q1 24 | $2.2B | $18.6M |
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | $2.5B | $1.5B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.5B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.7B | ||
| Q2 24 | $2.5B | $1.8B | ||
| Q1 24 | $2.6B | $2.0B |
| Q4 25 | $5.2B | $3.1B | ||
| Q3 25 | $5.0B | $3.0B | ||
| Q2 25 | $4.8B | $2.9B | ||
| Q1 25 | $4.6B | $2.7B | ||
| Q4 24 | $4.8B | $2.6B | ||
| Q3 24 | $5.1B | $2.6B | ||
| Q2 24 | $5.0B | $2.4B | ||
| Q1 24 | $4.8B | $2.3B |
| Q4 25 | $9.2B | $8.0B | ||
| Q3 25 | $9.0B | $7.8B | ||
| Q2 25 | $8.8B | $7.6B | ||
| Q1 25 | $8.5B | $7.3B | ||
| Q4 24 | $8.7B | $7.2B | ||
| Q3 24 | $9.2B | $7.2B | ||
| Q2 24 | $8.9B | $7.1B | ||
| Q1 24 | $8.7B | $7.1B |
| Q4 25 | 0.48× | 0.48× | ||
| Q3 25 | 0.50× | 0.51× | ||
| Q2 25 | 0.52× | 0.53× | ||
| Q1 25 | 0.55× | 0.56× | ||
| Q4 24 | 0.53× | 0.59× | ||
| Q3 24 | 0.49× | 0.64× | ||
| Q2 24 | 0.51× | 0.78× | ||
| Q1 24 | 0.53× | 0.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $239.9M |
| Free Cash FlowOCF − Capex | $215.2M | $-64.6M |
| FCF MarginFCF / Revenue | 20.5% | -8.7% |
| Capex IntensityCapex / Revenue | 1.4% | 40.9% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.95× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $-21.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $239.9M | ||
| Q3 25 | $355.1M | $251.1M | ||
| Q2 25 | $343.3M | $195.7M | ||
| Q1 25 | $169.4M | $183.9M | ||
| Q4 24 | $189.3M | $163.1M | ||
| Q3 24 | $367.0M | $151.1M | ||
| Q2 24 | $405.8M | $170.4M | ||
| Q1 24 | $292.4M | $90.4M |
| Q4 25 | $215.2M | $-64.6M | ||
| Q3 25 | $341.4M | $28.6M | ||
| Q2 25 | $330.5M | $-26.3M | ||
| Q1 25 | $153.9M | $41.4M | ||
| Q4 24 | $172.5M | $26.8M | ||
| Q3 24 | $350.6M | $64.0M | ||
| Q2 24 | $385.3M | $26.1M | ||
| Q1 24 | $279.6M | $-66.4M |
| Q4 25 | 20.5% | -8.7% | ||
| Q3 25 | 32.5% | 3.7% | ||
| Q2 25 | 32.3% | -3.5% | ||
| Q1 25 | 15.3% | 5.9% | ||
| Q4 24 | 16.9% | 4.0% | ||
| Q3 24 | 35.5% | 9.2% | ||
| Q2 24 | 38.1% | 3.9% | ||
| Q1 24 | 27.5% | -11.1% |
| Q4 25 | 1.4% | 40.9% | ||
| Q3 25 | 1.3% | 28.4% | ||
| Q2 25 | 1.3% | 29.2% | ||
| Q1 25 | 1.5% | 20.2% | ||
| Q4 24 | 1.6% | 20.6% | ||
| Q3 24 | 1.7% | 12.6% | ||
| Q2 24 | 2.0% | 21.6% | ||
| Q1 24 | 1.3% | 26.3% |
| Q4 25 | 1.28× | 1.95× | ||
| Q3 25 | 1.90× | 2.45× | ||
| Q2 25 | 1.76× | 2.71× | ||
| Q1 25 | — | 2.41× | ||
| Q4 24 | 0.94× | 4.39× | ||
| Q3 24 | 2.05× | 3.65× | ||
| Q2 24 | 2.09× | 3.23× | ||
| Q1 24 | 1.72× | 3.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
LTH
| Membership | $535.1M | 72% |
| In Center | $191.2M | 26% |
| Other | $18.8M | 3% |
